ArticleFrontiers in cardiovascular medicine2026
Patient perspectives of prosthetic heart valve choice and anticoagulation in patients with rheumatic heart disease: a semi-quantitative study.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To understand the factors that influence rheumatic heart disease (RHD) patients' prosthetic heart valve choice, their knowledge of anticoagulation and subsequent experience. This is the first RHD-specific data on valve choice, including high-deprivation populations. Methods: We performed a semi-quantitative, retrospective, cross-sectional survey study using a semi-structured telephone interview of patients (18-60 years) with RHD who had undergone valve replacement surgery from 2015 to 2020 at a single centre. Patients shared their experiences with prosthetic heart valves and warfarin. Results: 138 patients completed or partially completed the survey from a total sample of 218 patients; mean age was 49 ± 10. 133 (61%) of patients had bioprosthetic valves implanted, and 85 (39%) had mechanical valves implanted. Younger and older patients were more likely to have bioprosthetic valves implanted, whereas middle-aged patients were more likely to have mechanical valves implanted. 38 (44%) of bioprosthetic valve patients specified warfarin avoidance, and 31 (62%) of mechanical valve patients specified avoidance of reoperation as their primary reason for choosing their respective valves (from 136 patients). 37 (43%) of bioprosthetic valve patients were informed that the durability of their valves would be at least 10-15 years (from 136 patients). The most helpful information providers regarding valve type were the surgeon and the cardiologist, whereas the GPs and cardiologists were for warfarin management. 64 (47%) had not seen a dentist, and 46 (34%) had not followed up with a cardiologist post-operatively (from 137 patients). Conclusion: Many young RHD patients receive bioprosthetic valves; surgeons and cardiologists greatly influenced this choice. A uniform evidence-based education programme for health professionals may enhance decision-making around valve choice. Key findings: A large proportion of young RHD patients receive bioprosthetic valves, and surgeons and cardiologists greatly influenced this choice. Many patients also do not see a dentist or cardiologist following surgery. A uniform evidence-based education programme for health professionals may enhance decision-making around valve choice, and free dental care and robust follow-up pathways would ensure this vulnerable group of patients is not lost to follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.